http://www.ncbi.nlm.nih.gov/pubmed/22593449

Anticancer Res. 2012 May;32(5):1705-10.

Utility of Insulin-like Growth Factor Receptor-1 Expression in Gefitinib-Treated Patients with Non-small Cell Lung Cancer.

Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi P.

Source

1725 W. Harrison St. Ste 809, Chicago, IL 60612, U.S.A. mary_fidler@rush.edu.

Abstract

BACKGROUND:

Insulin-like growth factor receptor 1 (IGF1R) is a proposed mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Newer agents targeting this pathway make it of clinical interest. This study evaluates the IGF1R expression in regard to outcomes and molecular markers of EGFR activity in lung cancer patients treated with gefitinib.

MATERIALS AND METHODS:

Gefitinib-treated patients with sufficient archived tissue were included. The IGF1R activity was measured by immunohistochemistry and the EGFR by immunohistochemistry, fluorescent in situ hybridization, and gene mutation testing. Logistic regression and cox proportional hazards models were used.

RESULTS:

A total of 83 patients were included in the study: 71% were positive for IGF1R expression which was not associated with EGFR parameters or clinical outcomes. Exploratory analyses showed counter-intuitive improved outcomes with co-expression of IGF1R and EGFR.

CONCLUSION:

IGF1R expression measured by immunohistochemistry does not appear to be related to gefitinib resistance